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Abstract
Background: Barriers to HIV testing experienced by individuals at risk for HIV can result in treatment delay and
further transmission of the disease. Instruments to systematically measure barriers are scarce, but could contribute
to improved strategies for HIV testing. Aims of this study were to develop and test a barriers to HIV testing scale in
a Swedish context.
Methods: An 18-item scale was developed, based on an existing scale with addition of six new items related to
fear of the disease or negative consequences of being diagnosed as HIV-infected. Items were phrased as
statements about potential barriers with a three-point response format representing not important, somewhat
important, and very important. The scale was evaluated regarding missing values, floor and ceiling effects,
exploratory factor analysis, and internal consistencies.
Results: The questionnaire was completed by 292 adults recently diagnosed with HIV infection, of whom 7 were
excluded (≥9 items missing) and 285 were included (≥12 items completed) in the analyses. The participants were
18–70 years old (mean 40.5, SD 11.5), 39 % were females and 77 % born outside Sweden. Routes of transmission
were heterosexual transmission 63 %, male to male sex 20 %, intravenous drug use 5 %, blood product/transfusion 2 %,
and unknown 9 %. All scale items had <3 % missing values. The data was feasible for factor analysis (KMO = 0.92) and a
four-factor solution was chosen, based on level of explained common variance (58.64 %) and interpretability of factor
structure. The factors were interpreted as; personal consequences, structural barriers, social and economic security, and
confidentiality. Ratings on the minimum level (suggested barrier not important) were common, resulting in substantial
floor effects on the scales. The scales were internally consistent (Cronbach’s α 0.78–0.91).
Conclusions: This study gives preliminary evidence of the scale being feasible, reliable and valid to identify different
types of barriers to HIV testing.
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Background
About 35 million individuals in the world are currently liv-
ing with HIV infection [1]. Of these, an increasing number
have access to antiretroviral treatment (ART), which has
substantially improved survival where treatment is avail-
able [2–4]. Early detection of HIV infection is vital for both
treatment and prevention. Timely initiation of ART in-
creases survival [2, 5] and significantly reduces the risk of
further transmission [6]. In addition, people who are aware
of their HIV infection often make behavioral changes to re-
duce the risk of onward transmission of HIV [7].
In Sweden, ART is generally accessible at no cost for all
who are diagnosed with HIV and eligible for treatment.
Despite this, a majority are diagnosed late [8], i.e. after
when treatment is recommended to start according to na-
tional guidelines [9]. Identification of potential barriers to
HIV testing is important for development of relevant
strategies to promote testing and reach individuals with un-
diagnosed HIV infection. Health care professionals could
benefit from knowing what patients perceive as barriers to
HIV testing, as this knowledge could direct them on how
to more actively initiate and encourage testing among
patients. On the societal level, knowledge about existing
barriers can give guidance on relevant targets for HIV
prevention on a structural level (e.g. laws, infrastructure).
Well-known barriers to HIV testing include perceived
low risk of HIV infection, structural barriers, concerns
about confidentiality, and fears of the disease or of nega-
tive consequences of being diagnosed as HIV-infected,
such as HIV-related stigma (for reviews of the literature,
see [10–13]). It is advantageous to use structured and
psychometrically tested instruments to assess barriers to
HIV testing, since such instruments are evaluated for
their qualities and give comparable results about the
existence and magnitude of different barriers in various
contexts. A few specific instruments to measures
barriers to HIV testing have been published [14–17] of
which only the scale by Awad et al. [14] has been evalu-
ated for psychometric properties. There is also one psy-
chometrically tested scale on attitudes to HIV testing
which investigates both barriers and positive attitudes to
HIV testing [18, 19]. The existing scales constitute an
important basis for further investigation of barriers to
HIV testing. However, our clinical experience from HIV
health care in Sweden suggests that the existing scales
do not include all barriers that are relevant, why an
extended scale is needed. Therefore, the aims of the
present study were to develop and test a barriers to HIV
testing scale relevant for a Swedish context.
Methods
Design
This was a cross-sectional study within the Swedish na-
tional project “Late Presentation of HIV-1 infection” lead
by Karolinska University Hospital, Sweden. Aim of the
national project was to identify factors in HIV-infected
patients and the health care system that contribute to
late diagnosis. The project is described elsewhere [20].
Eligible for participation were adults living in Sweden,
diagnosed with HIV infection from October 2009 to
January 2012, with data collected within six months after
their diagnosis.
Instrument development
For the present study, an 18-item scale was developed,
based on twelve items from the existing barriers to HIV
testing scale by Awad et al. [14] and six new items. Di-
mensions measured in the original scale are structural
barriers, fatalism/confidentiality concerns, and fears.
The scale was evaluated and translated into Swedish by
a bilingual panel of HIV experts. One item concerning
costs of treatment was excluded in the new scale due to
the general availability of treatment for free in Sweden.
The six new items were added, based on the literature
and clinical experiences, to expand on different feared
consequences of being diagnosed with HIV [12, 13, 20].
Appropriateness of the content and phrasings of the
new items was discussed with professionals from partici-
pating clinics. Three of the new items concerned potential
consequences in social contacts and relationships of
being diagnosed with HIV: fear of losing one’s family or
friends (e.g. [21–24]) and fear of negative consequences
in sexual life [25]. The remaining three items con-
cerned other potential negative consequences for the
individual of being diagnosed with HIV infection: fear
of becoming ill [12, 13], worries about legal conse-
quences [10] and fear of feeling like a failure. The topic
of fear of legal consequences has been shown relevant
from an international perspective [10] and is, according
to clinical experiences and previous research [26] also
relevant for a Swedish context where people living with
HIV under the law are obligated to disclose their HIV
status to sexual partners and when seeking health care.
The eighteen items were phrased as statements about
potential barriers and the respondents are instructed to
rate the importance of the barriers described on a
three-point scale from 0–2. The response alternatives
and their respective scores are not important (0),
somewhat important (1), and very important (2). The
simple response format was chosen to make the scale
feasible for a broad population of respondents, includ-
ing people with limited language skills and literacy.
Swedish and English versions of the scale were
developed simultaneously (new items in English adapted
by the bilingual expert panel). Items in the scale, titled
the Barriers to HIV Testing Scale – Karolinska version,
are presented in Table 1.
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Participants
Patients from three of the largest HIV clinics in Sweden
and eight county clinics distributed throughout the
country were eligible for participation in the present
substudy. Inclusion criteria were being ≥ 18 years old
and diagnosed with HIV infection up to 6 month before
completion of the questionnaire. Since a majority of
those living with HIV infection in Sweden are migrants
and since individuals not speaking and understanding a
main language are often excluded from research, an
explicit goal of the study was to also include individuals
with low comprehension of Swedish.
The inclusion process is presented in Fig. 1. Of 445
eligible participants, 308 chose to participate in the
study, and 292 completed the barrier questionnaire.
Seven participants had missing values on half of the
items or more and were excluded. The remaining 285
individuals had completed at least two thirds of the
items and were included in the psychometric evaluation.
The participants were between 18 and 70 years old
(mean 40.5, SD 11.5), 39 % were females and 77 % born
outside Sweden. Routes of transmission were heterosex-
ual transmission (HT) 63 %, male to male sex (MSM)
20 %, intravenous drug use (IDU) 5 %, blood product/
transfusion 2 %, and unknown 9 % (Table 2). Sixteen
percent of the participants completed the Swedish
Table 1 Items, and factor loadings based on principal axis factoring with oblimin rotation (pattern matrix) in the Barriers to HIV
Testing Scale – Karolinska version (N = 258)
Item Factors
1a 2b 3c 4d
16. I was afraid of becoming sick .823 .122 .103 -.077
15. I was afraid that my sex life would be negatively affected .809 -.044 -.131 .121
18. I was worried about feeling like a failure .691 .078 .048 -.230
14. I was afraid of losing my friends and other social contacts .480 -.116 -.358 -.224
12. I was afraid of losing my partner .455 .029 -.395 -.057
17. I was worried about the legal consequences .450 .068 -.341 -.085
9. I did not want to know the results .399 .326 .033 -.222
4. The testing site was too far away .016 .699 .033 .060
1. I did not have transportation to a testing site .029 .663 .051 -.046
8. There was no cure so why get tested -.025 .634 .036 -.266
3. I did not have enough time .078 .632 -.081 .157
2. I did not know where to go for testing -.118 .532 -.303 -.039
5. I did not like people at testing site .085 .344 -.092 -.169
11. I was afraid of losing my job -.011 .050 -.795 -.081
13. I was afraid of losing my family .206 .097 -.582 -.146
10. I was worried about my insurance/insurances .123 .147 -.488 -.092
6. I was worried about confidentiality .030 .077 -.185 -.744
7. People might recognize me at testing site .230 -.046 -.141 -.550
The factors were interpreted as relating to: apersonal consequences, bstructural barriers, csocial and economic barriers, dconfidentiality
Items assigned to scale with highest loading (in bold)
Non-participants: 
Declined n = 53
Severe illness or deceased n= 30
Moved abroad or to non-study site n = 17
Language difficulties n = 6
Miscellaneous logistic n = 31
Severe illness or deceased n= 5
Moved abroad or to non-study site n = 2
Miscellaneous logistic n = 9
Missing ≥9 items n = 7
Included in the psychometric evaluation (≥12 
items completed) n = 285
Filled out barrier questionnaire n = 292
Agreed to participate n = 308
Eligible for participation N = 445
Fig. 1 Flowchart of inclusion of participants in the study
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version of the questionnaire with assistance of a profes-
sional interpreter (in-person or by telephone), who
translated the items into the respondents’ language of
origin. The English version of the questionnaire was
used by 27 % of the participants. Participants did not
differ from non-participants regarding sex, age or route
of transmission, but were less likely to be born outside
Sweden (OR 0.51, CI 0.32–0.80, p 0.004). Furthermore,
the participants were representative for the total popula-
tion of individuals with newly diagnosed HIV in Sweden
during the study period (N = 827) [27] with regard to
gender and origin, but were slightly older (mean age
40.5 vs. 38.9, t(284) 2.35, p 0.020) and had a lower repre-
sentation of individuals with MSM as route of transmis-
sion (OR 0.68, CI 0.49–0.94, p 0.018).
Procedures
Eligible patients were informed about the study by their
treating physician in connection with a visit at their out-
patient clinic. They were given oral and written informa-
tion about the purpose of the study and the voluntary
nature of participation. The barrier questionnaires were
administered by staff at the clinic, who could also an-
swer questions regarding the questionnaire. Professional
interpreters were available in-person or by telephone for
participants who did not speak Swedish or English.
Demographic data was collected from the Swedish
InfCare HIV registry [27]. The study was approved by
the Regional Ethical Review Board of Stockholm,
Sweden (2009/1029-31/1-4).
Statistical analyses
Participants were compared with non-participants and
population data with Pearson’s chi-square tests for di-
chotomous data (each route of transmission dichoto-
mized as present/absent) and t-tests for continuous data
(independent two-samples t-test and one-sample t-test
for comparisons with non-participants and population
data, respectively). Data quality was assessed by inspec-
tion of missing values, means and standard deviations as
well as floor and ceiling effects. Items were considered
feasible if they had less than 3 % missing values [28].
Questionnaires with at least two thirds of the items
completed were considered acceptable for the data ana-
lyses, except for the factor analysis which was calculated
on complete questionnaires. Evidence for construct
validity was investigated with exploratory factor analysis.
The sample size was considered adequate for exploratory
factor analysis of the 18-item questionnaire [29]. The
Kaiser-Meyer-Olkin measure of sampling adequacy
(KMO) [30] and Bartlett’s test of sphericity were used to
determine adequacy of the data for factor analysis [31].
Factors were extracted with principal axis factoring.
Oblimin rotation was used since the factors were ex-
pected to be related [32]. The final factor solution was
based on comprehensibility and interpretability together
with level of explained variance. Scales were constructed
from the factors, where items with loadings ≥ 0.32 [32]
were assigned to the scale with the highest loading.
Items with loadings ≥ 0.32 on two or more scales were
considered as cross-loading items [32]. Scale means were
calculated by averaging completed items on each scale.
Scale reliabilities were assessed with Cronbach’s α [33],
where the reliability was interpreted as; α ≥ 0.9 excellent,
0.7 ≤ α < 0.9 good, 0.6 ≤ α < 0.7 acceptable, 0.5 ≤ α < 0.6
poor, and α < 0.5 unacceptable [34]. Bivariate correla-
tions between scales were calculated with Spearman’s
rho. All statistical analyses were conducted with IBM
SPSS 22 (IBM Corp., Armonk, NY).
Results
Feasibility
All items were well accepted by the responding patients
with less than 3 % missing values for each item.
Factor analysis
The exploratory factor analysis (Table 1) was based on
258 complete questionnaires. The data was judged
feasible for factor analysis (KMO 0.916, Bartlett’s test of
sphericity χ[153] 2768.91, p <0.001). The factor analysis
with principal axis factoring and oblimin rotation en-
abled different factor solutions. Eigenvalues > 1 sug-
gested a three factor solution and solutions with three to
five factors were evaluated. A four-factor solution,
explaining 58.6 % of the common variance, was finally
chosen based on interpretability and level of variance ex-
plained. Four items had cross-loadings (loadings > 0.32).
Fear of losing one’s partner, fear of losing one’s friends
and other social contacts, and worries about legal conse-
quences, loaded most strongly on the personal conse-
quences factor but also had substantial loadings on the
Table 2 Description of the participants: percentages of sex,
origin and paths of transmission (N = 285)
%
Women 39
Origin
Sweden 23
Other countries 77
Path of transmission
Heterosexual 63
Male to male sex 20
Intravenous drug use 5
Blood product/ transfusion 2
Unknown 9
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social and economic security factor. Not wanting to
know the results loaded most strongly on personal con-
sequences but also had substantial loading on structural
barriers. The assignment of cross-loading items to the
factor with its highest loading was further motivated by
the content of these items, which was judged to corres-
pond well with the factor it was assigned to. The sug-
gested factors are presented below (new items marked
with *).
Factor 1, Personal consequences
This factor consisted of seven potential barriers relating
to fear of consequences for the individual; fear of be-
coming ill*, fear of negative consequences for sexual
life*, worries about feeling like a failure*, fear of losing
friends and social contacts*, fear of losing partner, wor-
ries about legal consequences*, and not wanting to know
the result.
Factor 2, Structural barriers
This factor consisted of six potential barriers relating to
external barriers; not having transportation to a testing
site, not knowing where to go for testing, not having
enough time, too long distance to the testing site, not
liking people at the testing site, and not testing because
there is no cure.
Factor 3, Social and economic security
This factor consisted of three potential barriers concern-
ing fear of losses related to job, family*, and insurances.
Common for these barriers was that they are related to
the social and economic security for both the individual
and his or her family.
Factor 4, Confidentiality
This factor consisted of two potential barriers concern-
ing confidentiality; worries about confidentiality and fear
of being recognized at the testing site.
Scale characteristics
Means, standard deviations, and floor and ceiling effects
for the four scales are presented in Table 3. All response
alternatives were used for all items, but the response alter-
native “not important” was most frequently used, resulting
in substantial floor effects on all scales. Approximately
one third of all respondents reported that none of the
barriers had importance for their decision to get HIV
tested. The bivariate correlations between the scales are
presented in Table 4. Moderate to strong positive correla-
tions (Spearman’s rho 0.478–0.709) were found between
the subscales.
Reliability
The internal consistencies of the scales were acceptable
to excellent (personal consequences α 0.91, structural
barriers α 0.78, social and economic barriers α 0.81, and
confidentiality α 0.81).
Discussion
The present study shows preliminary feasibility, reliabil-
ity, and internal validity of the 18-item Barriers to HIV
Testing Scale – Karolinska version, measuring four di-
mensions of barriers to HIV testing at the individual
level: personal consequences, structural barriers, social
and economic security, and confidentiality concerns.
Structural barriers and confidentiality concerns are well
known barriers to HIV testing and these factors were
similar to those in the original 13-item barrier scale by
Awad et al. [14]. Fear is also a well-known barrier to
HIV testing, including fear of social and economic
losses, fear of being stigmatized and fear of becoming ill.
In the Barriers to HIV Testing Scale – Karolinska ver-
sion, fear and worries were reflected in two subscales,
personal consequences and social and economic security.
The two subscales are interpreted as mirroring two
facets of fear for negative consequences of being diag-
nosed with HIV. The personal consequences scale is
interpreted as reflecting fear relating to identity and per-
sonal needs, and the social and economic security scale
is interpreted as reflecting fear on a more tangible level,
relating to the social and economic security for the indi-
vidual and his or her family. Since the two scales were
highly correlated, it remains to test the scales’ predictive
value in future studies to prove the usefulness of retain-
ing two separate fear scales [28].
Substantial floor effects, reflecting a high proportion of
participants reporting no barriers on the dimension mea-
sured, were found on all scales. A high rate of responses
Table 3 Descriptive statistics for the Barriers to HIV Testing Scale – Karolinska version: number of items per scale, means, standard
deviations (SD), floor and ceiling effects, and Cronbach’s α (N = 285)
Scalea No. of items Mean SD Floor/ceiling effects (%)b α
Personal consequences 7 0.47 0.61 48.8/3.5 0.91
Structural barriers 6 0.24 0.40 58.2/0.7 0.78
Social and economic security 3 0.31 0.57 68.8/5.3 0.80
Confidentiality 2 0.48 0.70 61.4/11.9 0.80
aPossible range for all scales: 0–2, higher levels indicating more barriers
bPercentage of ratings at the lowest/highest possible score
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on the minimum level is problematic for instruments
intended to evaluate small differences between groups or
individuals, or changes on individual levels over time [28].
However, the Barriers to HIV Testing Scale – Karolinska
version was developed mainly to identify types of barriers
in different populations and different contexts. Low rat-
ings on a scale in a population would just indicate that the
type of barrier measured is not a major obstacle to HIV
testing in that population. On the other hand, low ratings
on all suggested barriers, as in the present sample, might
also be a reflection of low perceived risk. Low perceived
risk has been identified as a major barrier to HIV testing
among groups with increased HIV prevalence [10, 12, 13].
It is difficult to compare our results with other studies,
since the number of negative responses are seldom sum-
marized and reported. However, in a study of barriers to
HIV testing among individuals concurrently diagnosed
with HIV and AIDS by Mills et al. [16] a majority of the
respondents endorsed only “not perceiving oneself to be
at risk for HIV” from a list of suggested barriers. Similarly,
in the study by Awad et al. [14] the highest mean scale
score was 1.54 on a scale from 1 (not important) to 3 (very
important), implying that it was common on all the three
scales, to experience a suggested barrier as not important
for the decision not to test for HIV. Low perceived risk
was not the focus of the present study, but from a HIV
prevention perspective, mapping and quantification of
people’s perception of risk appears important to investi-
gate together with the measurement of other barriers.
Future studies might consider the inclusion of items
covering low perceived risk to develop the scale further.
Furthermore, the Barriers to HIV Testing Scale –
Karolinska version was adapted for individuals living in
Sweden and an item relating to treatment cost from the
scale by Awad et al. [14] was excluded since HIV treat-
ment is free of cost in Sweden. Although the item lacks
relevance in Sweden, future studies might consider the
inclusion or exclusion of a treatment cost item based
on its relevance in the context studied.
This study aimed at including a representative sample
of newly diagnosed individuals with HIV in Sweden.
Therefore, individuals with limited knowledge in
Swedish were purposely included. This strategy results
in possible limitations as well as strengths of the study.
The additional use of English versions and interpreters
for those who did not speak Swedish could be consid-
ered a methodological weakness. However, the items
were short straightforward statements and the expert
panel had no difficulty in coming to agreement on the
proper translation of items into Swedish or English. A
definite strength was that all groups living with HIV in
Sweden today were well represented. Of those who
agreed to participate in the study, a large percentage
completed the questionnaire with relatively few missing
items, which indicates that the scale is comprehensible
and acceptable for the relevant populations.
Conclusions
The 18-item Barriers to HIV Testing Scale – Karolinska
version shows adequate psychometric properties to
identify different types of barriers to HIV testing. This
study adds to previous research by offering an instru-
ment that distinguishes between feared personal conse-
quences for the individual and feared social and
economic consequences that might involve both the
individual and her or his family.
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